NCT02285179 - Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen | Biotech Hunter

Enrollment

189

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

May 1, 2022

Study Completion Date

May 1, 2022

Conditions

Breast Cancer

Interventions

DRUG

GDC-0032

Dose of GDC-0032 given orally, once daily (total daily dose) level -1: 2 mg Q.O.D GDC-0032 level 1: (starting) 2 mg QD for 21 days, 7 days off and tamoxifen 20 mg qd level 2: 4 mg QD for 21 days, 7 days off and tamoxifen 20 mg qd

DRUG

Tamoxifen

daily dose of 20 mg

Trial Locations (14)

Unknown

Gustave Roussy, Paris

Reinier de Graaf Gasthuis, Delft

Deventer Ziekenhuis, Deventer

Ziekenhuis Groep Twente, Hengelo

MUMC, Maastricht

Haaglanden Medisch Centrum, The Hague

Hospital Germans Trias i Pujol, Badalona

Hospital Clínic de Barcelona, Barcelona

Hospital ICO-Hospitalet (Bellvitge), Barcelona

Hospital Arnau de Vilanova, Lleida

Hospital Universitari Sant Joan de Reus, Tarragona

1066 CX

Antoni van Leeuwenhoek, Amsterdam

080035

Vall d'Hebron University Hospital/VHIO, Barcelona

CB20QQ

University of Cambridge, Cambridge